AGM Statement and Result of AGM

May 30, 2018

At the AGM held earlier today the CEO, Jeremy Haigh, made a brief statement: “As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT® strengthens.   Trading is broadly in line with expectations despite a characteristically slower first quarter, and the services business continues to demonstrate significant growth.   While the Company remains cash constrained, we have had discussions with a number of our larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business.”

All resolutions at the AGM were duly passed.

Back to News